CD274 and hepatocellular carcinoma: ,10,11, 12, 13 Subsequently, the phase III IMBRAVE-150 trial investigating the combination of the anti-programmed death-ligand 1 (PD-L1) atezolizumab with the anti-VEGF bevacizumab demonstrated an advantage over sorafenib in terms of both OS and PFS, thus leading to the approval of the combination as first-line new standard of care for advanced HCC.14